Clinical trials

Artificial intelligence
#AI / data analytics / healthtech / informatics #Antibodies #Antibody-based therapeutics #Artificial intelligence (AI) #Clinical trial design #Clinical trials #Start-ups

New podcast: Innovative applications of AI in drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative applications of AI in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Decoding diseases: The AI renaissance in clinical trials” and “Advancing antibody… Read More

#News

Molecular,Model,Of,Antibody
#Antibody #Clinical trials #Haematology #Harvard Medical School #ITP #Monoclonal antibodies #Platelet biology #Takeda

Mezagitamab and the future of ITP treatment

The International Society on Thrombosis and Haemostasis (ISTH) 2025 Congress took place in Washington DC from 21-25 June 2025. At this event, Takeda presented final results from a Phase II trial evaluating mezagitamab (TAK-079), a potential best-in-class anti-CD38 monoclonal antibody (mAb), in patients with persistent or chronic primary immune thrombocytopenia… Read More

#Exclusive Content

#Clinical trials #Lung disease #Qureight

Synthetic study arms validate rare lung disease treatment

Qureight’s digitally-twinned synthetic control arm has been used in a breakthrough clinical trial application in place of a human placebo group, marking a world-first in lung disease research. The study, presented at the American Thoracic Society, demonstrates significant clinical efficacy for Avalyn’s inhaled pirfenidone (AP01), a promising treatment for idiopathic… Read More

#News

Blood cells
#Blood cancer #Clinical trials #EHA #Haematology #Oncology

Data highlights from EHA 2025

The latest new trial data presented at the 30th European Hematology Association (EHA) 2025 Congress.  Bispecific antibody for diffuse large B-cell lymphoma Genmab shared new results from the Phase Ib/II EPCORE NHL-2 trial Arm 10 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously,… Read More

#Cancer Research #News

Lungs
#Academic #Clinical trials #Fibrosis #Halo Biosciences #Hypertension #Lung disease #Stanford University

Study suggests new hope for pulmonary hypertension

Halo Biosciences has announced publication of results in Thorax from the Phase IIa SATURN study for patients with pulmonary hypertension and interstitial lung disease (PH-ILD). The study, conducted at Stanford University, evaluated 4-methylumbelliferone (4-MU) in patients with pulmonary hypertension, a highly progressive disease with significant unmet needs. The Phase IIa… Read More

#News

Antibodies
#Absci #Antibodies #Biologics #Biopharmaceuticals #Clinical trials

Absci becomes clinical-stage company with clinical trial initiation

Biopharmaceutical company Absci has transitioned into a clinical-stage organisation with the dosing of patients in its Phase I clinical trial of ABS-101. ABS-101 is the company’s investigational anti-TL1A antibody targeting inflammatory bowel disease, engineered using Absci’s generative AI platform. “We are excited to advance ABS-101 into Phase I clinical trials,”… Read More

#News

#Cancer research #Clinical trials #Oncology #OneOncology #Partnership #START Center for Cancer Research (START)

Strategic partnership to launch new clinical trial sites

The START Center for Cancer Research (START) and OneOncology has announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer and Blood Disorders (CCBD, Texas), and Astera Cancer Care (New Jersey). This arrangement builds on… Read More

#Cancer Research #News

Human neuron
#Augustine Therapeutics #Charcot-Marie-Tooth disease (CMT) #Clinical trials #Neurology #Neuroscience

First patient dosed with Charcot-Marie-Tooth disease treatment

Augustine Therapeutics has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective cytosolic Histone DeACetylase 6 (HDAC6) inhibitor for the treatment of Charcot-Marie-Tooth disease (CMT), an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain,… Read More

#News

#Clinical trials #Collaboration #Oncology

We need international partnerships to get new cancer drugs into the clinic

On International Clinical Trials Day, Lars Erwig, Director of the Centre for Drug Development at Cancer Research UK, calls for an international approach to clinical trials.  Launching a clinical trial for a new cancer treatment is a formidable challenge. For one thing, patient recruitment is arguably more difficult now than… Read More

#Cancer Research #Exclusive Content #Opinion

Neuron firing
#Clinical trials #Herantis Pharma #Parkinson's #The Michael J Fox Foundation for Parkinson’s Research (MJFF)

First patients dosed in Phase Ib Parkinson’s disease trial

Herantis Pharma has dosed the first patients in the final cohort of its Phase Ib clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Commenting on the study, Antti Vuolanto, CEO of Herantis Pharma, said: “Parkinson’s disease is a life altering condition, and there is… Read More

#News

Double stranded DNA molecule with mutation in a gene
#Clinical trials #Cystic fibrosis #Drug delivery #Drug development #Europe #Kither Biotech

In Conversation With: Dimitrios Goundis, Kither Biotech

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Dimitrios Goundis, CEO… Read More

#News

#Akiram Therapeutics #Clinical trials #Radiotherapy #Sweden

First patient enrolled in Phase I trial of Akiram’s cancer drug

Akiram Therapeutics, a Swedish biotech company specialising in targeted radiotherapy, has enrolled the first patient in the Phase I clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts… Read More

#Cancer Research #News

#Clinical trials #Diabetes #Multiple sclerosis #Oncology #Phase II trial #Phase III trial

New DDW Highlights podcast: 28 April 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With Eli Lilly so far winning the race to bring an oral GLP-1 drug… Read More

#News

#Clinical trials #Diabetes #Multiple sclerosis #Oncology #Phase II trial #Phase III trial

This week in drug discovery (21-25 April) 

News round-up for 21-25 April by DDW Senior Digital Content Editor Diana Spencer. With Eli Lilly so far winning the race to bring an oral GLP-1 drug to market, having announced positive topline results from a Phase III trial, this week our news highlights focus on clinical studies. Read More

#News

Quantum computing concept
#AI / data analytics / healthtech / informatics #Clinical trials #Computer modelling #Quantum computing

How quantum computing is revolutionising drug development

Saurabh Singal, Founder of Molecule AI, examines the impact that quantum computing can, and will have, on drug discovery and development. A quantum leap in pharma In 2019, Google announced that its quantum computer had achieved a groundbreaking milestone1 – solving a problem in 200 seconds that would take the… Read More

#Exclusive Content #Trends & Analysis

#Artificial intelligence (AI) #Clinical trial design #Clinical trials #European Medicines Agency #Liver disease

EMA qualifies first AI tool to diagnose liver disease in trials

The European Medicine Agency’s (EMA’s) human medicines committee (CHMP) has issued the first Qualification Opinion (QO) on a development methodology based on artificial intelligence (AI).   The tool, called AIM-NASH, helps pathologists analyse liver biopsy scans to identify the severity of MASH (metabolic dysfunction associated steatohepatitis; formerly known… Read More

#News